SPDR Portfolio Aggregate Bond ETF (ARCA: SPAB)

Latest news for SPDR Portfolio Aggregate Bond ETF (ARCA:SPAB)

SPDR Portfolio Aggregate Bond ETF

The fund generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index and in securities that the Adviser determines have economic characteristics that are substantially identical to the economic characteristics of the securities that comprise the index. The index is designed to measure the performance of the U.S. dollar denominated investment grade bond market.

john-o-nolan-uMWPrcRsrto-unsplash

ETFs

AAPL

HYLB

MSFT

SPAB

SUSA

ESG-Focused Fund SUSA Continues To Grow, Topping The Chart Two Weeks In A Row, Risky Bonds Fall - ETF Winners And Losers: Mid-Cap Flows

News

Market-Moving Exclusives

Exclusives

LSTA

EXCLUSIVE: Lisata Therapeutics Tells Benzinga Co. And Haystack Oncology Initiate Research Collaboration To Use The Haystack MRD Technology To Evaluate Efficacy Of Pancreatic Cancer Therapy

Piper Sandler analyst Mark Lear maintains Chord Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRD#NASDAQ">CHRD</a>) with a Overweight and raises the price target from $233 to $234.

Price Target

Analyst Ratings

CHRD

Piper Sandler Maintains Overweight on Chord Energy, Raises Price Target to $234

Haystack Oncology, a Quest Diagnostics Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DGX#NYSE">DGX</a>) company, announced a research collaboration with Lisata Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSTA#NASDAQ">LSTA</a>).
Haystack Oncology developed Haystack MRD, a next-generation tumor-informed approach to measure minimal residual disease. Haystack MRD uses an error-corrected ctDNA technology to detect down to one ctDNA molecule in a million normal DNA molecules.
Lisata Therapeutics is a clinical-stage pharmaceutical company developing innovative therapies for advanced solid tumors.
Under the agreement, Lisata will deploy the Haystack MRD technology to detect circulating tumor DNA (ctDNA) in a clinical study evaluating certepetide plus chemotherapy as an investigational treatment for metastatic pancreatic cancer.
In the FORTIFIDE study, Lisata is investigating the safety, tolerability, and efficacy of its lead product candidate, certepetide, when given as a 4-hour continuous infusion in combination with standard-of-care treatment in subjects with metastatic pancreatic ductal adenocarcinoma (mPDAC) who have progressed on FOLFIRINOX, a treatment for pancreatic cancer.
As part of this research, Lisata has engaged Haystack to use its MRD technology to measure serum ctDNA levels at multiple time points in patients throughout the study as an exploratory endpoint for analyzing the early therapeutic effect of certepetide.
The American Cancer Society estimates more than 66,000 individuals nationwide will be diagnosed with pancreatic cancer in 2024. mPDAC accounts for more than 90% of pancreatic cancer cases and is a highly aggressive form of the disease.
Most recently, Lisata Therapeutics announced the early completion of enrollment in its Phase 2a BOLSTER trial evaluating certepetide (formerly LSTA1), Lisata&#8217;s investigational product, as a treatment for <a target="_blank" href="https://www.benzinga.com/pressreleases/24/07/g39790403/lisata-therapeutics-announces-completion-of-enrollment-in-its-phase-2a-bolster-trial-of-certepetid" rel="noreferrer noopener">first-line cholangiocarcinoma</a>.
Price Action: DGX shares closed at $148.48, and LSTA shares closed at $3.66 on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/05/38842564/employers-struggle-with-drug-test-policies-amid-varying-state-laws-cheating-on-drug-tests-reaches-30" target="_blank" rel="noreferrer noopener">Employers Struggle with Drug Test Policies Amid Varying State Laws, Cheating on Drug Tests Reaches 30-Year High</a>.</li>
</ul>

Biotech

Health Care

Contracts

General

EXCLUSIVE: Haystack Oncology Inks Research Collaboration With Lisata Therapeutics To Use Haystack MRD Technology To Evaluate Pancreatic Cancer Therapy Efficacy

Stephens &amp; Co. analyst Terry McEvoy maintains Nicolet Bankshares (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIC#NYSE">NIC</a>) with a Equal-Weight and raises the price target from $90 to $110.

Stephens & Co. Maintains Equal-Weight on Nicolet Bankshares, Raises Price Target to $110

Lilium N.V.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LILM#NASDAQ">LILM</a>) shares are trading higher after it entered into a definitive sales agreement with Saudia Group or 50 Lilium Jets, with <a target="_blank" href="https://www.benzinga.com/pressreleases/24/07/g39832573/saudia-group-signs-industry-leading-sales-agreement-with-lilium-to-acquire-up-to-100-evtol-jets" rel="noreferrer noopener">options for an additional 50 aircraft</a>.
Following the Memorandum of Understanding signed between Saudia Group and Lilium in October 2022, this sales agreement represents a significant milestone in the industry.
The deal marks the largest reported firm order of eVTOL aircraft in the MENA region by an airline committed to operating these aircraft.
The agreement details payment schedules, delivery timelines, performance guarantees, and provisions for spare parts and maintenance.
Additionally, the parties aim to finalize a &#8220;Lilium POWER-ON&#8221; agreement for fleet maintenance and support.
Saudia Group anticipates receiving its first jets in 2026, managed by its subsidiary, Saudia Private.
Lilium&#8217;s agreement with Saudia Group expands its order pipeline, comprising 106 firm orders and reservations, 76 options, and around 600 aircraft under MOU.
H.E. Engr. Ibrahim Al-Omar, Director General of Saudia Group,&nbsp;said,&nbsp;&#8220;This agreement amplifies our commitment to the Saudi Vision 2030 and is the result of a collaborative effort over the past years between Lilium and Saudia Group to explore how we can best bring eVTOL to the skies of Saudi Arabia.&#8221;
&#8220;Business travelers and exhibition attendees will benefit tremendously from the ease and speed of electric aircraft, allowing them to seamlessly attend and participate in events. These innovative vehicles will also be a game-changer for tourism, sports, and entertainment, offering a premium travel experience for these exciting destinations.&#8221;
Lilium is also in advanced discussions with global airlines committed to reducing carbon emissions and adopting electric regional air travel.
Yesterday, Lilium confirmed its 2026 delivery schedule for the first customer shipments, following a recent program review that includes testing, validation, and preparations for the <a target="_blank" href="https://www.benzinga.com/pressreleases/24/07/g39812459/lilium-reaffirms-2026-target-for-first-customer-deliveries-and-provides-additional-detail-on-testi" rel="noreferrer noopener">first manned flight in early 2025</a>.
Price Action: LILM shares are up 2.98% at $0.9999 premarket at the last check Thursday.
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo via Shutterstock

Equities

Small Cap

Movers

LILM

Why Electric Aircraft Manufacturer Lilium Shares Are Surging Premarket Thursday

Piper Sandler analyst Mark Lear maintains APA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APA#NASDAQ">APA</a>) with a Neutral and raises the price target from $33 to $34.

Piper Sandler Maintains Neutral on APA, Raises Price Target to $34

JMP Securities analyst Silvan Tuerkcan maintains Relay Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RLAY#NASDAQ">RLAY</a>) with a Market Outperform and lowers the price target from $24 to $21.

RLAY

JMP Securities Maintains Market Outperform on Relay Therapeutics, Lowers Price Target to $21

WIIM

SAI.TECH Global shares are trading higher after the company's Board authorized a buyback of up to $1 million and up to 1 million shares.

Morgan Stanley analyst Alexandra Steiger maintains TJX Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TJX#NYSE">TJX</a>) with a Overweight and raises the price target from $113 to $122.

Morgan Stanley Maintains Overweight on TJX Companies, Raises Price Target to $122

Commodities

Markets

Reuters Reported OPEC+ Unlikely To Change Oil Output Policy At Aug 1 JMMC Meeting, Citing Sources

Cantor Fitzgerald analyst Troy Jensen initiates coverage on Impinj (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PI#NASDAQ">PI</a>) with a Overweight rating and announces Price Target of $205.

Initiation

Cantor Fitzgerald Initiates Coverage On Impinj with Overweight Rating, Announces Price Target of $205

Deutsche Bank analyst Krisztina Katai downgrades Five Below (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIVE#NASDAQ">FIVE</a>) from Buy to Hold and lowers the price target from $155 to $79.

Downgrades

FIVE

Deutsche Bank Downgrades Five Below to Hold, Lowers Price Target to $79

Alliance Global Partners analyst Gaurav Mehta initiates coverage on UMH Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UMH#NYSE">UMH</a>) with a Buy rating and announces Price Target of $21.

Alliance Global Partners Initiates Coverage On UMH Properties with Buy Rating, Announces Price Target of $21

Offerings

LUXH

LuxUrban Hotels Announced That The Underwriter Of Its Underwritten Public Offering Has Exercised Its Over-allotment Option In Full To Purchase An Additional 4.5M Shares At The Public Offering Price Of $0.17/Share

The Company plans to report the final analysis from the IGNITE clinical trial, including all patients at 12 months dosed with either 20 mg/kg or 40 mg/kg of iluzanebart in the first half of 2025. &nbsp;

VIGL

Vigil Neuroscience Announced An Update Following A Type C Meeting With The FDA To Its Clinical Development Strategy For Its IGNITE Trial Of Iluzanebart For Adult-onset Leukoencephalopathy With Axonal Spheroids And Pigmented Glia

B of A Securities analyst Tomer Zilberman maintains Motorola Solns (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSI#NYSE">MSI</a>) with a Buy and raises the price target from $370 to $440.

B of A Securities Maintains Buy on Motorola Solns, Raises Price Target to $440

B of A Securities analyst Elizabeth Suzuki maintains Leslies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LESL#NASDAQ">LESL</a>) with a Buy and lowers the price target from $6.4 to $5.15.

LESL

B of A Securities Maintains Buy on Leslies, Lowers Price Target to $5.15

The energy storage solutions will be used for Root-Power&#39;s Coryton Energy Park project, in Corringham, Essex, England. Construction of the project started in late May 2024.

CSIQ

Canadian Solar Announced That e-STORAGE, Part Of The Company's Majority-owned Subsidiary CSI Solar, Has Received A Contract For 11 MW AC/22 MWh AC Energy Storage Solutions From Root-power, Part Of The Ylem Group

Wayfair Plans Four Days Of Exclusive Sales For Black Friday In July; Up To 80% Off All Things Home July 26-29

FTNT

Fortinet shares are trading higher after TD Cowen upgraded the stock from Hold to Buy.